This book provides latest findings in organotypic models in drug development and provides the scientific resonance needed in an emerging field of research in disciplines, such as molecular medicine, physiology, and pathophysiology. Today the research on human-based test systems has gained major interest and funding in the EU and the US has increased over the last years. Moreover, so-called 3R (reduce, replace, refine animal experiments) centres have been established worldwide. 

Inflammatory skin disease models in vitro and in animals - predictability for drug development

Neural In Vitro Models for Studying Substances Acting on the Central Nervous System
Quality of commercial tissues Standardised Reconstructed Skin Models in Toxicology and Pharmacology: State of the Art and Future Development
Human-Derived In Vitro Models Used for Skin Toxicity Testing Under REACh
Disease Models: Lung models for testing drugs against inflammation and infection
In Vitro Models of the Blood-Brain Barrier
How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development
The CAM Assay as an Alternative In Vivo Model for Drug Testing
Organotypic Models in Drug Development "Tumor Models and Cancer Systems Biology for the Investigation of Anticancer Drugs and Resistance Development
Tissue Engineering for Musculoskeletal Regeneration and Disease Modeling
Immunocompetent human intestinal models in preclinical drug development
EngineeredHeart Muscle Models in Phenotypic Drug Screens.